JP2011518168A - ホスファチジルイノシトール３−キナーゼの阻害薬 - Google Patents

ホスファチジルイノシトール３−キナーゼの阻害薬 Download PDF

Info

Publication number
JP2011518168A
JP2011518168A JP2011505126A JP2011505126A JP2011518168A JP 2011518168 A JP2011518168 A JP 2011518168A JP 2011505126 A JP2011505126 A JP 2011505126A JP 2011505126 A JP2011505126 A JP 2011505126A JP 2011518168 A JP2011518168 A JP 2011518168A
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
composition
acceptable salt
aliphatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011505126A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011518168A5 (enExample
Inventor
ティアンシェン ワン，
アレキサンダー アロノフ，
マーク コーネバイス，
フランソワ マルテス，
マーク レドボアー，
ティラン， アーナウド ル
バレリー マローン，
デイビッド メサースミス，
ケビン コットレル，
ジョン エイチ． カム，
ガブリエル マルチネス ボテラ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of JP2011518168A publication Critical patent/JP2011518168A/ja
Publication of JP2011518168A5 publication Critical patent/JP2011518168A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2011505126A 2008-04-16 2009-04-14 ホスファチジルイノシトール３−キナーゼの阻害薬 Withdrawn JP2011518168A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4546108P 2008-04-16 2008-04-16
US61/045,461 2008-04-16
US10289408P 2008-10-06 2008-10-06
US61/102,894 2008-10-06
PCT/US2009/040454 WO2009129211A1 (en) 2008-04-16 2009-04-14 Inhibitors of phosphatidylinositol 3-kinase

Publications (2)

Publication Number Publication Date
JP2011518168A true JP2011518168A (ja) 2011-06-23
JP2011518168A5 JP2011518168A5 (enExample) 2013-05-23

Family

ID=40833464

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011505126A Withdrawn JP2011518168A (ja) 2008-04-16 2009-04-14 ホスファチジルイノシトール３−キナーゼの阻害薬

Country Status (9)

Country Link
US (1) US20110135603A1 (enExample)
EP (1) EP2283013A1 (enExample)
JP (1) JP2011518168A (enExample)
CN (1) CN102083826A (enExample)
AU (1) AU2009236380A1 (enExample)
CA (1) CA2721434A1 (enExample)
MX (1) MX2010011370A (enExample)
NZ (1) NZ588700A (enExample)
WO (1) WO2009129211A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011522024A (ja) * 2008-06-04 2011-07-28 アストラゼネカ アクチボラグ 抗細菌薬としてのチアゾロ［５，４−ｂ］ピリジンおよびオキサゾロ［５，４−ｂ］ピリジン誘導体

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7928140B2 (en) 2007-08-02 2011-04-19 Amgen Inc. Benzothiazole PI3 kinase modulators for cancer treatment
EP2401273A1 (en) 2009-02-27 2012-01-04 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
LT2496567T (lt) 2009-11-05 2017-11-27 Rhizen Pharmaceuticals S.A. Nauji benzopirano kinazės moduliatoriai
PT2705029T (pt) 2011-05-04 2019-02-01 Rhizen Pharmaceuticals S A Novos compostos como moduladores de proteína quinases
PT2870157T (pt) 2012-07-04 2017-11-27 Rhizen Pharmaceuticals S A Inibidores seletivos de delta pi3k
CN104402875A (zh) * 2014-12-25 2015-03-11 西安山川医药科技有限公司 N-(2-氨基乙基)-n′-(6-取代-2-苯并噻唑基)脲及其盐类化合物的合成方法和用途
WO2025165930A1 (en) * 2024-01-31 2025-08-07 Biogen Ma Inc. Methods for treating spinal muscular atrophy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20070978A1 (es) * 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
JP5336375B2 (ja) * 2006-08-30 2013-11-06 セルゾーム リミテッド キナーゼ阻害剤としてのトリアゾール誘導体
CN101801966A (zh) 2007-07-18 2010-08-11 诺瓦提斯公司 双环杂芳基化合物和它们作为激酶抑制剂的用途
US7928140B2 (en) * 2007-08-02 2011-04-19 Amgen Inc. Benzothiazole PI3 kinase modulators for cancer treatment

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011522024A (ja) * 2008-06-04 2011-07-28 アストラゼネカ アクチボラグ 抗細菌薬としてのチアゾロ［５，４−ｂ］ピリジンおよびオキサゾロ［５，４−ｂ］ピリジン誘導体

Also Published As

Publication number Publication date
EP2283013A1 (en) 2011-02-16
CA2721434A1 (en) 2009-10-22
CN102083826A (zh) 2011-06-01
AU2009236380A1 (en) 2009-10-22
WO2009129211A1 (en) 2009-10-22
US20110135603A1 (en) 2011-06-09
NZ588700A (en) 2012-07-27
MX2010011370A (es) 2010-12-15

Similar Documents

Publication Publication Date Title
AU2007290359B2 (en) 5- (2-furyl)-1, 3-thiazole derivatives useful as inhibitors of phosphatidylinositol 3-kinase
AU2010341573B2 (en) Isoindolinone inhibitors of phosphatidylinositol 3-kinase
JP2012529525A (ja) ホスファチジルイノシトール３−キナーゼの阻害薬
EP2032562B1 (en) Selective inhibitors of rock protein kinase and uses thereof
US8481538B2 (en) Heterocyclic inhibitors of c-Met and uses thereof
US20110135603A1 (en) Inhibitors of phosphatidylinositol 3-kinase
JP2012519177A (ja) 三環式ピラゾロピリジンキナーゼインヒビター
KR20080080584A (ko) ｃ-Ｍｅｔ의 억제제 및 이의 용도
AU2008257044A1 (en) Thiazoles and pyrazoles useful as kinase inhibitors
AU2010216219A1 (en) Tetrahydrothiazolopyridine inhibitors of phosphatidylinositol 3-kinase
JP2013506691A (ja) ホスファチジルイノシトール３−キナーゼのピラゾール阻害薬
HK1155440A (en) Inhibitors of phosphatidylinositol 3-kinase
HK1133873A (en) 5-(2-furyl)-1, 3-thiazole derivatives useful as inhibitors of phosphatidylinositol 3-kinase

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120314

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120314

A072 Dismissal of procedure [no reply to invitation to correct request for examination]

Free format text: JAPANESE INTERMEDIATE CODE: A073

Effective date: 20130718

A300 Application deemed to be withdrawn because no request for examination was validly filed

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20130806